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Objectives: Drug delivery systems consisting of liposomes displaying a cell surface 
receptor-targeting peptide are being developed to specifically deliver chemotherapeutic drugs 
to tumors overexpressing a target receptor. This study addresses novel liposome composition 
approaches to specifically target tissues overexpressing bombesin (BN) receptors.
Methods: A new amphiphilic peptide derivative (MonY-BN) containing the BN(7–14) peptide, 
the DTPA (diethylenetriaminepentaacetate) chelating agent, a hydrophobic moiety with two C
18
 
alkyl chains, and polyethylene glycol spacers, has been synthesized by solid-phase methods. 
Liposomes have been generated by co-aggregation of MonY-BN with 1,2-distearoyl-sn-glycero-
3-phosphocholine (DSPC). The structural and biological properties of these new target-selective 
drug-delivery systems have been characterized.
Results: Liposomes with a DSPC/MonY-BN (97/3 molar ratio) composition showed a diameter 
of 145.5 ± 31.5 nm and a polydispersity index of 0.20 ± 0.05. High doxorubicin (Dox) loading was 
obtained with the remote pH gradient method using citrate as the inner buffer. Specific binding 
to PC-3 cells of DSPC/MonY-BN liposomes was obtained (2.7% ± 0.3%, at 37°C), compared 
with peptide-free DSPC liposomes (1.4% ± 0.2% at 37°C). Incubation of cells with DSPC/
MonY-BN/Dox showed significantly lower cell survival compared with DSPC/Dox-treated 
cells, in the presence of 100 ng/mL and 300 ng/mL drug amounts, in cytotoxicity experiments. 
Intravenous treatment of PC-3 xenograft-bearing mice with DSPC/MonY-BN/Dox at 10 mg/kg 
Dox dose produced higher tumour growth inhibition (60%) compared with nonspecific DSPC/
Dox liposomes (36%) relative to control animals.
Conclusion: The structural and loading properties of DSPC/MonY-BN liposomes along with the 
observed in-vitro and in-vivo activity are encouraging for further development of this approach 
for target-specific cancer chemotherapy.
Keywords: bombesin peptide, doxorubicin delivery, gastrin-releasing peptide receptors, 
PC-3 cells, theranostic applications
Introduction
Conventional doxorubicin (Dox) is an established cytotoxic agent for many cancer 
types (in particular, breast and ovarian cancer), and its use has been shown to be 
clinically effective. However, irreversible cardiac toxicity has been one of the primary 
dose-limiting factors in the use of this drug1 and, consequently, many research efforts 
have been directed towards improving its safety profile. A successful strategy for 
reducing the cardiac toxicity associated with conventional Dox involves encapsulation 
into liposomes, which alters the tissue distribution and pharmacokinetics of this drug 
while maintaining efficacy and improving the therapeutic index.2,3 Liposomal Dox 
formulations (eg, Myocet® and Caelyx®/Doxil®) have shown reduced cardiac toxicity 
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compared with free Dox4–6 while preserving antitumor 
efficacy. The prolonged circulation times obtainable with 
this strategy, in particular for pegylated (Stealth) liposomes, 
allows preferential accumulation in tumor tissues given their 
leaky vasculature and poorly operating lymphatic system 
(enhanced permeability and retention effect).7–10
All liposomal drugs presently marketed, as well as others 
now in development, are based on “nonspecific” liposomes. The 
development of new nanovectors able to selectively deliver a 
chemo-therapeutic agent to cancer cells, may lead to increased 
therapeutic efficacy of the encapsulated drug, as well as reduce 
toxic side effects on nontarget cells.11 Peptides and antibodies 
have been largely investigated as bioactive markers used to 
confer selectivity to liposomes to target cells.12–14 It is well 
known that regulatory peptides, and fragments thereof, bind 
with high affinity to specific cell-surface receptors. Receptor 
systems such as the somatostatin (SSTR1-SSTR5) receptors,15 
the vasoactive intestinal peptide receptor,16 cholecystokinin 2/
gastrin (CCK
2
) receptors,17 gastrin-releasing peptide (GRP)/
bombesin (BN) receptors,18 and several others,19 are known to 
be overexpressed in specific human cancer types.
The authors of this present study have previously studied 
nanosized delivery systems, such as micelles and liposomes, 
modified with bioactive peptides on their external surface; 
these have been obtained by combining two different 
amphiphilic monomers, one containing a bioactive peptide 
(CCK8, Octreotide, or BN[7–14]) and the other containing a 
chelating agent (DTPAGlu, DTPA, or DOTA). Moreover, the 
authors also studied liposomes prepared by co-aggregation of 
a synthetic amphiphilic monomer containing both the bioac-
tive peptide and the chelating agent, with commercial phos-
pholipids. In both cases, targeted nanocarriers engineered 
to conjugate imaging and therapeutic functions20–24 were 
obtained for potential theranostic applications. Deriva-
tized nanosystems, capable of diagnosis, drug delivery, 
and monitoring of therapeutic response, are expected to 
play a significant role in the dawning era of personalized 
medicine.25,26
Interesting results have been obtained by using the BN 
peptide.27 The 14-residue BN peptide, its eight-residue 
C-terminal peptide sequence (BN[7–14]), or other BN ana-
logues acting as antagonists may be used to target BN receptor 
subtype 2, also known as gastrin releasing peptide receptor 
(GRPR). GRP receptors have been found overexpressed in 
cell lines derived from several human tumor types (ovarian 
cancer, breast cancer, and prostate cancer).28–30 Many stud-
ies demonstrate that the BN(7–14) fragment modified on its 
N-terminus with radiometal complexes, for diagnostic or ther-
apeutic nuclear medicine applications, preserves its affinity for 
these receptors.31–33 In-vitro and in-vivo experiments,  carried 
out on radiolabeled liposomes containing the BN(7–14) 
peptide fragment, demonstrate that the peptide, exposed on 
the liposome surface, maintains the capability to selectively 
target aggregates to GRPR-expressing xenografts.27
This paper describes new BN-conjugated nanosystems 
for theranostic purposes with improved properties, both in 
the synthesis and formulation aspects and for their in-vitro 
and in-vivo behavior. These liposomes are based on the co-
aggregation of 1,2-distearoyl-sn-glycero-3-phosphocholine 
(DSPC) phospholipid with a new synthetic amphiphilic 
monomer, MonY-BN (Figure 1), containing in the same mol-
ecules the BN(7–14) peptide fragment, the DTPA chelating 
agent, the hydrophobic moiety with two C18 alkyl chains, 
and polyethylene glycol (PEG) spacers.
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Figure 1 Schematic representation of MonY-Peg27(DTPA)-BN (MonY-BN).
Notes: MonY-BN molecule contains five components: a hydrophobic moiety with two C18 alkyl chains, a long polyoxoethilene spacer (Peg27), the DTPA chelating agent, 
a short linker (Ahoh), and the BN(7–14) peptide. The peptide sequence is reported using the three-letter amino acid code.
Abbreviations: BN, bombesin; DTPA, diethylenetriaminepentaacetate; PEG, polyethylene glycol.
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Materials and methods
Instrumentation
Preparative high-performance liquid chromatography (HPLC) 
was carried out on an LC8 Shimadzu HPLC system 
(Shimadzu Corporation, Kyoto, Japan) equipped with a 
UV lambda-Max Model 481 detector using a Phenomenex 
(Torrance) C4 (300 Å, 250 mm × 21.20 mm, 5 µ) column 
eluted with an H
2
O/0.1% trifluoroacetic acid (TFA) and 
CH
3
CN/0.1% TFA from 20% to 95% over 25 minutes at 
20 mL/min flow rate. Liquid chromatography coupled to 
mass spectrometry (LC–MS) analyses were performed 
by using Finnigan Surveyor MSQ single quadrupole 
electrospray ionization (Finnigan/Thermo Electron 
Corporation, San Jose, CA). Ultraviolet (UV) measurements 
were performed on a UV-vis Jasco V-5505spectrophotometer 
equipped with a Jasco ETC-505T Peltier temperature 
controller with a 1-cm quartz cuvette (Hellma, Müllheim, 
Germany).
Pharmaceuticals and reagents
Protected Nα-Fmoc-amino acid derivatives, coupling 
reagents, and Rink amide MBHA resin were purchased from 
Calbio-chem-Novabiochem (Laufelfingen, Switzerland). 
The Fmoc-21-amino-4,7,10,13,16,19-hexaoxaheneicosanoic 
acid (Fmoc-Ahoh-OH) was purchased from Neosystem 
(Strasbourg, France). N,N-dioctadecylsuccinamic acid was 
prepared according to the experimental procedure reported 
in the literature.34 α-(9-Fluorenylmethyloxycarbonyl) 
amino-ω-carboxy PEG (Fmoc-NH-Peg27-COOH) was 
purchased from Iris Biotech GmbH (Marktredwitz, Germany). 
DTPA(OtBu)
4
-OH (diethylenetriaminepentaacetate tetra-tert-
butyl ester) was purchased from Macrocyclics (Dallas, TX). 
Citrate acid, sodium citrate, sodium chloride, and Dox were 
obtained from Sigma Chemical Co (St Louis, MO). All other 
chemicals were commercially available from Sigma-Aldrich, 
Fluka (Bucks, Switzerland) or LabScan (Stillorgan, Dublin, 
Ireland) and were used as received unless otherwise stated. 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC) was purchased 
from Lipoid GmbH (Cam, Switzerland). All solutions were 
prepared by weight using doubly distilled water.
Peptide synthesis
Synthesis of (C18h37)2NCO(Ch2)2CO-Peg27-
Lys(DTPA)-Ahoh-Gln-Trp-Ala-Val-Gly-his-Leu-Met-
Amide (MonY-BN)
Synthesis of MonY-BN was carried out in solid-phase 
under standard Fmoc strategy,35 with a 433A Applied 
Biosystems (Foster City, CA) automatic synthesizer. 
Rink-amide MBHA resin (0.78 mmol/g, 0.5 mmol scale, 
0.640 g) was used. The elongation of BN(7–14) peptide 
(sequence: -Gln-Trp-Ala-Val-Gly-His-Leu-Met-Amide) 
was achieved by sequential addition of Fmoc-AA-OH 
with benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate/1-hydroxy-1,2,3-benzotriazole/
N,N-diisopropylethylamine (PyBOP/HOBt/DIPEA) (1:1:2) 
as coupling reagents, in N,N-dimethylformamide (DMF) in 
pre-activation mode. All couplings were performed twice 
for 1 hour by using an excess of four equivalents of each 
amino acid derivative. Fmoc deprotection was obtained 
with a 30% solution of piperidine in DMF. When peptide 
synthesis was complete, the Fmoc N-terminal protecting 
group was removed and a residue of Fmoc-Ahoh-OH 
was condensed in a single coupling by using an excess 
of two equivalents. The resin was then washed, the ter-
minal Fmoc protection removed and 1.064 g (2.0 mmol) 
of Dde-Lys(Fmoc)-OH were coupled to the resin by 
stirring the slurry suspension under standard conditions. 
The Fmoc-protecting group was removed by standard 
conditions, and the DTPA(OtBu)
4
-OH tetraester chelat-
ing agent was linked, through its free carboxyl function, 
to the ε-NH
2
 of the lysine residue. This coupling step was 
performed using two equivalents of DTPA-tetraester and 
O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
(HATU), and four equivalents of DIPEA in DMF. The 
coupling time for this step was increased to 2 hours. 
Removal of the Dde group was obtained by incubation 
with a DMF/hydrazine (98:2) mixture and the Fmoc-
NH-Peg27-COOH linker was coupled overnight by using 
HATU/DIPEA as activating agents and DMF as solvent. 
The N-terminal Fmoc protecting group was removed, and 
1.244 g (2.0 mmol) of N,N-dioctadecylsuccinamic acid in 
N,N-dimethylformamide/dichloromethane (DMF/DCM) 
(1:1) mixture were condensed. Coupling was repeated 
twice for 1 hour. Peptide derivative was cleaved from the 
resin with TFA (5 mL) containing 2.5% (v/v) water and 
2.0% (v/v) tri-isopropylsylane (TIS) as scavengers at room 
temperature for 2 hours. Free peptide was precipitated 
in cold ethyl ether and lyophilized from a H
2
O/CH
3
CN 
(50/50) solution. Crude peptide was purified by reversed 
phase HPLC, and each fraction was characterized by 
LC–MS analysis.
(C
18
H
37
)
2
NCO(CH
2
)
2
CO-Peg27-Lys(DTPA)-Ahoh-
Gln-Trp-Ala-Val-Gly-His-Leu-Met-Amide; MonY-BN: 
Rt = 15.5 min; (MW = 3669) [M + 4H]+/4 = 923 amu.
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Synthesis of (C18h37)2CONhLys-(DTPA)CONh2 
[(C18)2DTPA]
The (C
18
H
37
)
2
CONHLys-(DTPA)CONH
2
 [(C
18
)
2
DTPA] 
monomer was synthesized according to the experimental 
procedure previously described.23
Liposome preparation and Dox loading
The liposomes were prepared by a modified reverse-phase 
evaporation technique. The lipid mixture composed of 
DSPC (7.90 mg) or DSPC/MonY-BN (7.66 mg DSPC, 
1.10 mg MonY-BN; 1:0.03 molar ratio) was dissolved in a 
chloroform/methanol (2:1 v/v) mixture. The organic solution 
was added to a 50 mL round-bottom flask, and the solvent was 
removed under reduced pressure in a rotary evaporator under 
nitrogen atmosphere. The resulting lipid film was dissolved 
in 3 mL diethyl ether, and the solution was emulsified, by 
sonication for 30 minutes in a bath-type sonicator (Branson 
3510, Danbury, CT), with 1 mL of citrate buffer at pH 4,0 
(150 mM of citric acid; 150 mM of sodium citrate) or with 
1 mL of ammonium sulfate buffer, 250 mM, at pH 5.5, in 
the presence of glass beads. The resulting emulsion was 
then placed on a rotary evaporator (Laborota 4010 digital, 
Heidolph, Schwabach, Germany), and the organic solvent 
was removed under reduced pressure at 30°C in nitrogen 
atmosphere. When the viscous gel was obtained, the vacuum 
was broken and the gel was vortexed for about 1 minute. The 
dispersion was then placed in the rotary evaporator under 
vacuum for about 15 minutes. Citrate or ammonium buffer 
(1 mL) was subsequently added, and the suspension heated 
at 65°C for 30 minutes. The resulting liposome suspen-
sion was extruded at 65°C, using a thermobarrel extruder 
system (Northern Lipids Inc, Vancouver, BC), passing the 
suspension repeatedly under nitrogen through a polycarbonate 
membrane (Nucleopore Track Membrane 25 mm, Whatman, 
Brentford, UK) with 0.1 µm pore size. The external buffer 
was removed by ultracentrifugation (Optima Max E, Beckman 
Coulter, Brea, CA; rotor TLA 120.2) at 80,000 rpm, at 4°C 
for 30 minutes, and the liposomes were resuspended with 
1 mL of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES)-buffered saline (HBS) at pH 7.4 (20 mM of HEPES; 
150 mM of sodium chloride), giving a suspension with a 
total lipid concentration of 0.010 M. The actual phospholipid 
 concentration of liposomes was determined according to 
Stewart’s assay.36 Briefly, an aliquot of the liposome suspension 
was added to a two-phase system, consisting of an aqueous 
ammonium ferrothiocyanate solution (0.1 N) and chloroform. 
The concentration of DSPC was obtained by measuring the 
absorbance at 485 nm in the organic layer.
Dox was encapsulated into liposomes by remote loading. 
Briefly, the liposome suspension was combined with the 
Dox at a drug/lipid ratio of 0.2 (w/w), and then incubated 
at 65°C for 1 hour. The amount of unencapsuleted Dox was 
determined as follows: 1 mL of liposome dispersion was 
ultracentrifugated at 80,000 rpm and 4°C for 30 minutes, 
the supernatant was carefully removed, and Dox concentra-
tion was determined with a UV-visible spectrophotometer 
at 480 nm. The results have been expressed as encapsula-
tion efficiency, calculated as [(TS
Dox
 − AS
Dox
)/TS
Dox
] × 100, 
where TS
Dox
 is the theoretical Dox in the supernatant before 
encapsulation, and AS
Dox
 is the actual Dox concentration in 
the supernatant. All liposome preparations were stored at 
4°C. Each formulation was prepared in triplicate.
Empty liposomes of DSPC/MonY-BN (3%) and DSPC/
(C18)
2
DTPA (0,1%) were also prepared with the same 
procedure for cell binding experiments.
Liposomes characterization
The mean diameter of the liposomes was determined at 20°C 
by photon correlation spectroscopy (PCS) (N5, Beckman 
Coulter. Each sample was diluted in deionizer/filtered water 
(0.22 µm pore size, polycarbonate filters, MF-Millipore, 
Microglass Heim, Italy) and analyzed with α detector at 
α 90° angle. As a measure of the particle size distribution, 
the polydispersity index (PI) was used. For each batch, 
mean diameter and size distribution were the mean of three 
measurements. For each formulation, the mean diameter and 
PI were calculated as the mean of three different batches. The 
zeta-potential (ζ) of the liposome surface was measured in 
water by means of a Zetasizer Nano Z (Malvern, UK). Data 
of ζ were collected as the average of 20 measurements.
Preparation of radiolabeled liposomes
Radiolabeling of the DSPC/MonY-BN (3%) and DSPC/
(C18)
2
DTPA (0.1%) liposomes was performed at a final 
concentration of 2 × 10−4 M. Trace amounts of 111InCl
3
 
(1 µCi) were added to 1 mL of the liposomes, and 1 mL of 
MilliQ water was added to reach a final volume of 2 mL. The 
mixture was incubated for 120 minutes at room temperature. 
Confirmation of incorporation of the label into the liposomes 
was obtained by gel filtration on Sephadex G-50 pre-packed 
columns (Pharmacia Biotech, Piscataway, NJ).
In-vitro studies
PC-3 cells were seeded into 6-well plates wherein they 
remained overnight (0.8–1.0 × 106 cells per well). On the 
day of the experiment, the medium was removed, and the 
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cells were washed twice with fresh medium (DMEM with 
10% fetal bovine serum, 1% L-glutamine) and incubated 
for 1 hour at 4°C and at 37°C. Internalization experiments 
of the 111In-labeled liposomes were performed by adding 
100 µL 111In-labeled liposomes (0.05 µCi) to triplicate wells 
at a final concentration of 2 × 10−4 M and incubated for 1 hour 
at 37°C.21 Afterwards, the binding buffer was removed, 
and the cells were washed twice with ice-cold phosphate-
buffered saline (PBS) (pH 7.4). Cell bound radioactivity 
was subsequently recovered by trypsinization of the wells. 
Radioactivity in the bound and free fractions was determined 
with a Wizard gamma-counter (Wallac, Turku, Finland).
Cytotoxicity assay
Cytotoxicity of Dox-loaded liposomes, DSPC/MonY-BN/
Dox, and DSPC/Dox and of free Dox was determined 
using the colorimetric MTS (3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)- 
2H-tetrazolium, inner salt) assay. Briefly, 8000 PC-3 cells/well 
were plated in 96-well plates and incubated overnight to 
allow cell attachment. The culture medium was removed, 
and cells were incubated with free Dox and liposomes con-
taining 100 and 300 ng/mL Dox. Total lipid concentration in 
the cells was 500 ng and 1500 ng for the two Dox amounts, 
respectively. After 8 hours, the medium was removed and 
the cells were incubated for an additional 72 hours in fresh 
medium. Plates were then incubated with 20 µL of MTS in 
100 µL of culture medium. Finally, 25 µL of 10% SDS was 
added to all wells to stop the reaction, and mixed thoroughly. 
The absorbance was measured with a BioRad 680 microtiter 
plate reader (BioRad, BioRad, Corston, UK) at a wavelength 
of 490 nm. Cells incubated with Dox-free liposomes were 
used as control. Viability was expressed as percentage of 
control (mean ± standard error of the mean [SEM]) for each 
condition. The experiment was performed at least three times 
with triplicate wells. IC
50
 values for each treatment condition 
were calculated graphically.
In-vivo experiments
Animal experiments were carried out on 6-week-old female 
BALB/c nude mice (Harlan Nossan, Italy). Mice bearing 
PC-3 xenografts of PC-3 cells were generated as previ-
ously described.13 Briefly, 100 µL of the cell suspensions at 
a density of 2–3 × 107 mL−1 in PBS with 0.1% glucose and 
mixed with an equal volume of Matrigel™ (BD Biosciences, 
Bedford, MA) were injected subcutaneously into the flank 
of mice (weighing 17–23 g). All procedures were performed 
inside a laminar air-flow cabinet using aseptic technique. 
Tumor growth was measured every other day, starting 
28 days following cell inoculation, using a digital caliper 
(Biological Instruments, Besozzo, VA, Italy). Approximately 
5 weeks after cell implantation, when tumors reached an 
average volume of 200–250 mm3, mice were randomly dis-
tributed into three groups (n = 5) and intravenously (lateral 
tail vein) administered with 100 µL of the following sterile 
formulations: saline buffer (control), DSPC/MonY-BN/
Dox (10 mg Dox/kg) and DSPC/Dox (10 mg Dox/kg). 
Drug dosage was adjusted with sterile PBS according to 
mean bodyweight for each group. Mice bodyweights were 
monitored twice a week following treatment. General animal 
health conditions were also evaluated to detect potential 
side effects, including food and water withdrawal, impaired 
movement, bodyweight loss, or behavioral changes. Proce-
dures involving animals and their care were in conformity 
with institutional guidelines that comply with national and 
international laws and policies.
Tumor growth was then monitored for the following 
22 days. The experiment was ended once control tumors 
reached a volume close to 1000 mm3, which was prior 
to deterioration of the animals’ health condition. Tumor 
growth curves, obtained by plotting tumor volume (mm3) 
versus treatment days, were determined for the different 
experimental groups. Percentage tumor growth inhibition 
(TGI) was determined as a measure of therapeutic activity 
for each treated group. All animal experiments complied 
with the Italian DL n 116 of 27 January 1992 and associate 
guidelines in the European Community Council Directive of 
24 November 1986 (86/609/ECC).
Results and discussion
Design and synthesis
The synthetic monomer, herein identified as MonY-BN 
for its Y shape (Figure 1), is a single molecule containing 
the following: (a) the hydrophobic moiety with two C
18
 
alkyl chains that allows intercalation of the monomer in 
liposomal structures; (b) the BN(7–14) peptide that allows 
the interaction of the reconstituted aggregates with GRPRs 
overexpressed by cancer cells; and (c) the DTPA chelating 
agent able to give stable complexes with different metal ions, 
such as the 111In(III) gamma-emitting isotope, used to monitor 
distribution through nuclear imaging techniques. Moreover, 
PEG and oxoethylene linkers have been introduced to space 
the bioactive peptide and the chelating agent from the two C
18
 
hydrophobic chains. The PEG moiety also increases the over-
all hydrophilicity of the molecule, improves peptide exposure 
away from the liposome surface, and should provide lower 
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clearance of the liposomes through the reticulo-endothelial 
system.37 The present authors previously studied supramo-
lecular aggregates containing a MonY-CCK8 monomer or 
MonY-octreotide monomer intercalated in DOPC liposomes; 
the design of MonY-BN has been further optimized by using 
a long-chain PEG (MW = 1500 Dalton) spacer to distance 
the DTPA chelating agent from the hydrophobic moiety in 
order to favor the packing of the hydrocarbon chains in stable 
and well defined liposomes.
From a synthetic point of view, the MonY-BN monomer 
is based on a lysine scaffold. The ahoh oxyethylene spacer is 
linked on the lysine C-terminus and the BN(7–14) peptide; 
the DTPA chelating agent is bound, through an amide bond, 
on the lysine side-chain, while the N-alpha lysine function 
is functionalized with a long PEG containing 27 oxyethyl-
ene groups, acting as spacer, and the hydrophobic moiety 
consisting of two alkyl chains with 18 carbon atoms each.
The chemical synthesis was performed in solid-phase by 
using standard solid-phase-peptide-synthesis (SPPS) proce-
dures based on Fmoc/tBu chemistry.35 Rink-amide resin was 
used to obtain a C-terminal amide peptide and the peptide built 
on the resin by sequential coupling and deprotection steps for 
the eight amino acid residues (see Figure 2). When the pep-
tide synthesis was complete, the Fmoc N-terminal protecting 
group was removed and a residue of Fmoc-Ahoh-OH was 
added. Then, Dde-Lys(Fmoc)-OH was coupled, the Fmoc 
protecting group removed and the DTPA(OtBu)
4
-OH tet-
raester chelating agent was linked, through its free carboxyl 
function, to the ε-NH
2
 of the lysine residue. After removal 
of the Dde group of the lysine residue, Fmoc-NH-Peg27-
COOH linker and N,N-dioctadecylsuccinamic acid were 
sequentially condensed. The peptide derivative was cleaved 
from the resin, and free peptide precipitated in cold ethyl 
ether and lyophilized. The crude compound was purified by 
Fmoc-NH
1. DMF/Pip (70/30)
1. DMF/Pip (70/30)
Fmoc-QWAVGHLM-NH
X8
2. Fmoc-aa-OH
     HOBt, PyBop, DIPEA
1. DMF/Pip (70/30)
Fmoc-Ahoh-QWAVGHLM-NHDde-Lys-Ahoh-QWAVGHLM-NH
Dde-Lys-Ahoh-QWAVGHLM-NH
DTPA(OtBu)4
Fmoc
2. Dde-Lys(Fmoc)-OH
     HOBt, PyBop, DIPEA
1. DMF/Pip (70/30)
2. DTPA(OtBu)4-OH
     HATU, DIPEA
1. DMF/Hydrazine (98/2) Fmoc-Peg27-Lys-Ahoh-QWAVGHLM-NH
DTPA(OtBu)42. Fmoc-NH-Peg27-COOH
    HATU, DIPEA
1. DMF/Pip (70/30)
CH2CH2-CO-NCH2CH2-CO-N
CO
NH
DTPA
Peg27-Lys-Ahoh-QWAVGHLM-CONH2
(CH2)17CH3
(CH2)17CH3
(CH2)17CH3
(CH2)17CH3 CO
NH
Peg27-Lys-Ahoh-QWAVGHLM-NH
DTPA(OBtu)4
2. N,N-Dioctadecylsuccinamic acid
     HOBt, PyBop, DIPEA
TFA/TIS/H2O (92.5/2.0/2.5)
2. Fmoc-Ahoh-OH
     HOBt, PyBop, DIPEA
Figure 2 Synthetic procedure for obtaining MonY-BN by solid-phase methods.
Notes: The empty circle, ○, represents the solid support (Rink amide resin). The first step of the scheme reports the Fmoc removal by using DMF/Pip (70/30) mixture and 
the amino acid (Fmoc-aa-Oh) coupling under standard SPPS conditions. This step is repeated eightfold to obtain the BN(7–14) sequence (reported according the single-letter 
amino acid code). Successively, solid-phase synthesis continues to bind on the peptide N-terminus to the other organic components. In the last step, cleavage (TFA/TIS/H2O) 
from the resin is performed to give a fully unprotected carboxamide product.
Abbreviations: BN, bombesin; DMF, N,N-dimethylformamide; DTPA, diethylenetriaminepentaacetate; PEG, polyethylene glycol; SPPS, solid-phase-peptide-synthesis; TFA, 
trifluoroacetic acid; TIS, tri-isopropylsylane.
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reversed phase HPLC and characterized by LC–MS analysis 
and Maldi-Tof.
Liposome preparation and characterization
Liposomes composed of DSPC (7.90 mg) or DSPC/
MonY-BN (7.66 mg DSPC, 1.10 mg MonY-BN; 97/3 molar 
ratio) were prepared in HBS buffer solution (1.0 mL) at a final 
lipid concentration 0.010 M, and fully characterized. This 
formulation resulted from a preliminary phase of the study 
in which increasing amounts of MonY-BN were added into 
the bilayer with different lipid compositions. In this phase, 
in order to achieve a liposomal formulation with a mean 
diameter suitable for tumor targeting and with a homoge-
neous size distribution, a mean diameter lower than 200 nm 
and a PI lower than 0.2, were considered pre-requisites to 
propose the formulation for following in-vitro and in-vivo 
experiments.
The zeta potential (ζ), mean diameter, and PI of the 
selected formulations, namely liposomes based on DSPC 
or DSPC/MonY-BN (97/3 molar ratio) are summarized in 
Table 1. The inclusion of 3% (mol/mol) MonY in the DSPC 
liposome composition led to reduction of the average size, 
and this effect could be attributed to the surfactant proper-
ties of MonY-BN. Moreover, a significant decrease of the 
zeta potential value (from about −6.7 to −12.8 mV) was 
observed when using MonY-BN in the formulation. This 
result could be attributable to the four negative charges of 
the DTPA chelating agent and supports the presence of BN 
and/or DTPA on the outer vesicle membrane.
Subsequently, the drug-loading capability of DSPC/
MonY-BN (97/3 molar ratio) liposomes was investigated. 
Dox encapsulation into the liposomes was carried out by 
the remote-loading method at a drug/lipid (w/w) ratio of 0.2. 
This value was selected according to the diameter of lipo-
somes (d = 150 nm). In fact, the encapsulation efficiency of 
hydrophilic drugs such as Dox is related to the liposome size 
(eg, for Myocet®, d = 180 nm and drug/lipid is 0.27, while 
for Doxil®, d = 85 nm and drug/lipid decreases to 0.127). 
The experimental conditions, namely the buffer used in 
the internal aqueous phase, the incubation time, as well as 
the incubation temperature, were optimized to achieve a 
drug-loading content . 90%. The incubation time and tem-
perature of liposomes in the presence of Dox represent two 
key parameters, which significantly affect drug loading of 
liposomes. As expected, drug-loading capability of liposomes 
was enhanced by increasing temperature (data not shown). 
Due to the presence of the peptide sequence in the final lipo-
some formulation, an incubation temperature of 65°C was 
considered the upper limit. As it concerns incubation time, 
maximal drug loading was obtained at 1 hour while longer 
incubation time did not significantly change the encapsulation 
efficiency (data not shown). Moreover, liposome encapsula-
tion efficiency was investigated under ammonium and citrate 
buffers. Buffer conditions strongly affect the drug-loading 
capability of liposomes:38 when ammonium buffer was used, 
an encapsulation efficiency , 60% was obtained, while a Dox 
encapsulation efficiency of approximately 95% was observed 
when using a citrate buffer in the aqueous phase of the lipo-
somes (Table 1). As expected, liposome characteristics do 
not significantly change after Dox loading (Table 1).
In-vitro studies
Receptor-mediated cellular uptake at 1 hour of the targeted 
BN liposome formulation (DSPC/111In-MonY-BN) in PC-3 
cell lines at 4°C and 37°C, was estimated with gamma count-
ing experiments. To confirm the selective binding capability 
of the targeted liposomes, cellular uptake of radiolabeled 
pure DSPC liposomes was also performed for comparison. 
To prepare the radiolabeled control liposomes, a low amount 
(0.1%) of the amphiphilic monomer (C
18
)
2
DTPA was intro-
duced in DSPC liposomes. A small amount of this monomer 
does not significantly alter the size and shape of the liposomes 
(data not shown). A complete radiolabeling of the liposomes 
was performed at 2 × 10−4 M concentration by adding trace 
amounts of 111InCl
3
. Incorporation of the radioactive label 
into the aggregates was confirmed by gel filtration.
Table 1 Liposome characteristics
Formulations Composition  
of the lipid bilayer
Composition of  
the aqueous phase
Liposome diameter  
(nm) ± SD
PI ± SD ζ mV ± SD Dox encapsulation 
efficiency (%)
DSPC liposomes DSPC PBS 161.4 ± 20.1 0.09 ± 0.01 −6.7 ± 1.8 –
MonY liposomes DSPC/MonY-BN PBS 145.5 ± 31.5 0.20 ± 0.05 −12.8 ± 1.5 –
Dox-MonY 
liposomes
DSPC/MonY-BN Ammonium buffer 165.2 ± 42.0 0.24 ± 0.07 −12.8 ± 3.6 58.0 ± 19.0
Dox-MonY 
liposomes
DSPC/MonY-BN Citrate buffer 150.8 ± 28.3 0.13 ± 0.08 −12.0 ± 1.0 95.0 ± 2.7
Abbreviations: Dox, doxorubicin; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; PBS, phosphate-buffered saline; PI, polydispersity index; SD, standard deviation.
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Specific preferential binding to PC-3 cells of mixed 
liposomes containing the BN(7–14) peptide sequence was 
observed (2.7 ± 0.3, at 37°C), compared with the pure DSPC 
liposomes (1.4 ± 0.2 at 37°C) (see Figure 3), indicating 
preserved interaction of the BN(7–14) bioactive peptide on 
the external surface of the liposomes with the GRPR on the 
surface of the cells.
Cytotoxicity assays
The cytotoxic effect of DSPC/MonY-BN/Dox on PC-3 
prostate cancer cells was also assessed. PC-3 cells were 
exposed to liposome formulations (100 µL) containing 500 
or 1500 ng of lipids and 100 or 300 ng of Dox, respectively, 
for 8 hours, and the cell viability was measured by MTS 
assays (Figure 4). Incubation of cells with DSPC/MonY-BN/
Dox showed significantly lower cell survival compared with 
DSPC/Dox-treated cells in the presence of 100 ng/mL and 
300 ng/mL drug amounts. On the other hand, liposomal 
Dox below 100 ng/mL concentration showed no significant 
differences on cell survival. In experiments performed with 
free Dox, 50% cell killing was observed with 85 ng/mL of 
drug (data not shown). This result suggests a lower toxicity 
of the liposomal cytotoxic drug compared to the free-drug. 
This result is expected as when cells are exposed to free Dox 
and liposomal Dox for the same amount of time, free Dox is 
taken up much more rapidly.
The increased potency of DSPC/MonY-BN/Dox with 
respect to DSPC/Dox is fully attributed to Dox because 
control experiments with empty liposomes had no significant 
effect on cell viability.
In-vivo studies
Preliminary studies on the therapeutic efficacy of DSPC/
MonY-BN/Dox targeted liposomes compared with pure 
DSPC/Dox liposomes were conducted in PC-3 xenograft-
bearing mice, by treating mice with intravenous injections 
of 100 µL of liposome suspensions (1.0 × 10−2 M lipid 
concentration, at a dose of 10 mg of Dox/kg). Control 
experiments on mice treated with saline buffer were also 
performed. 1 × 106 cells per animal were injected in the flank 
of 6-week-old BALB/c nude mice in a solution containing 
1:1 Matrigel™.
Matrigel™ is an extract of basement membrane compo-
nents, which primarily consists of laminin, collagen IV, and 
heparin sulfate proteoglycan.39 Its co-injection with cancer 
cells into subcutaneous tissues aims to stimulate growth of 
biologically indolent tumors.40 Once the tumor model was 
established, another important challenge was to determine 
the most appropriate treatment experimental conditions 
with regard to tumor volume at the beginning of treatment, 
treatment groups, dose escalation, and end point conditions, 
such as duration of the observation period after treatment. 
After evaluating the influence of the referred experimental 
parameters, the treatment protocol was established: a single 
dose was administered intravenously at an advanced phase 
of tumor development (200–250 mm3). The experiment 
was stopped when untreated tumors reached a size close to 
1000 mm3. Bodyweights of all mice were recorded periodi-
cally to assess nonspecific toxicity. There were no signs of 
clinical toxicity, and all animals gained weight and survived 
the entire experimental period (data not shown).  Therapeutic 
efficacy was assessed by measuring tumor volume over 
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111In-radiolabeled 
liposomes on PC-3 cell line overexpressing the GRP at 37°C and 4°C at 1 hour.
Abbreviations: BN, bombesin; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; 
DTPA, diethylenetriaminepentaacetate; GRP, gastrin-releasing peptide.
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Figure 4 Cytotoxicity of liposomal Dox against human prostatic cancer cells.
Notes: PC-3 cells (8000 cells/well) were incubated with DSPC/MonY-BN/Dox, 
DSPC/Dox, and free Dox at 37°C (liposome formulations containing 500 or 
1500 ng of lipids and 100 or 300 ng of Dox, respectively). Control experiments 
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Abbreviations: BN, bombesin; Dox, doxorubicin; DSPC, 1,2-distearoyl-sn-glycero-
3-phosphocholine; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2h-tetrazolium; SEM, standard error of the mean.
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time. Data were expressed as mean ± SEM (n = 5) and 
analyzed using two-way analysis of variance followed by 
 Bonferroni’s test; a value of P , 0.05 was considered sta-
tistically significant.
Treatment with liposomal formulations was effective 
in slowing tumor progression over an extended period of 
time (see Figure 5). In particular, treatment with DSPC/
MonY-BN/Dox at 10 mg/kg Dox dose produced a TGI 
of 60%, compared with the treatment with saline buffer. 
Furthermore, a decrease in tumor growth was also observed 
(TGI = 36%), compared with mice treated with nonspecific 
liposomes of DSPC/Dox at the same Dox dose.
Conclusion
A new drug-delivery system, DSPC/MonY-BN (97/3 molar 
ratio), based on liposomes functionalized with the bioactive 
sequence of the BN peptide and with a chelating agent, has 
been developed by incorporating a new amphiphilic synthetic 
monomer, MonY-BN, in a liposome-forming commercial 
phospholipid, DSPC. The liposomes structure, the drug-
loading ability, the selective cellular binding and  cytotoxicity, 
and the in-vivo therapeutic efficacy were assessed. The 
simultaneous presence of the bioactive BN peptides, provide 
targeting ability for the liposomes, and of the chelating 
agents, which allow radiolabeling for diagnostic nuclear 
medicine applications, makes these liposomes potential 
target-selective theranostic agents.41
All the structural and loading properties, similar to other 
drug-delivery systems already in clinical use (eg, Myocet® 
and Caelyx®/Doxil®), and the observed in-vitro and in-vivo 
behaviors point toward a potential clinical use of the new 
liposomes for Dox delivery in cancer therapy. Areas of 
clinical interest are applications in patients with ovarian, 
breast, and prostate cancer, where a number of studies have 
documented the overexpression of GRPRs.28–30 The high 
incidence of these diseases and the lack of adequate treat-
ment strategies in advanced stages warrant development of 
more effective strategies.
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